Liver Fibrosis - Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 87
Inquire Before Buying

Liver Fibrosis - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Fibrosis.
- A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Liver Fibrosis - Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Liver Fibrosis 10
Liver Fibrosis Therapeutics under Development by Companies 12
Liver Fibrosis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Liver Fibrosis Therapeutics - Products under Development by Companies 19
Liver Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Liver Fibrosis Therapeutics Development 21
Bristol-Myers Squibb Company 21
Gilead Sciences, Inc. 22
FibroGen, Inc. 23
Silence Therapeutics plc. 24
Genfit 25
La Jolla Pharmaceutical Company 26
LG Life Sciences, Ltd 27
Digna Biotech, S.L. 28
7TM Pharma A/S 29
GenKyoTex S.A. 30
Angion Biomedica Corp. 31
Virobay Inc. 32
Liver Fibrosis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
FG-3019 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TM-38837 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GFT-505 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P-17 Systemic - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GM-CT-01 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VBY-376 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BB-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GKT-137831 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
candesartan cilexetil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
irbesartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GS-6624 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CIGB-500 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AB-0023 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AM-095 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Raltegravir + Ritonavir-Boosted Protease Inhibitor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cytopro - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GM-CT-02 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GR-MD-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GR-MD-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ANG-4011 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-351 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Liver Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ANG-3298 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LC-280126 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79
Liver Fibrosis - Product Development Milestones 80
Featured News & Press Releases 80
Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports 80
Aug 07, 2012: Galectin Therapeutics Plans Clinical Trials For Early 2013 To Treat Fatty Liver Disease With Advanced Fibrosis After Recent FDA Meeting 80
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 81
May 10, 2012: Genfit Announces Preclinical Data Of GFT505 Promotes Liver Fibrosis Regression 82
Dec 16, 2011: Galectin Therapeutics Presents Preclinical Data On Treatment Of Fatty Liver Disease And Fibrosis At EASL 82
Nov 02, 2011: Promedior Announces Presentation Of Preclinical Data At AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis 83
Jul 12, 2011: GENFIT Announces First Results Of GFT505-210-5 Clinical Trial In Diabetic Patients 83
Apr 11, 2011: Fragment Of RegeneRx's Tß4 Inhibits Activation Of Liver Cells Responsible Fibrosis And Scar Formation 84
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 84
Oct 14, 2010: FibroGen Initiates Phase II Clinical Study To Evaluate Efficacy Of FG-3019 In Reversing Liver Fibrosis 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bristol-Myers Squibb Company, H2 2012 21
Gilead Sciences, Inc., H2 2012 22
FibroGen, Inc., H2 2012 23
Silence Therapeutics plc., H2 2012 24
Genfit, H2 2012 25
La Jolla Pharmaceutical Company, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Digna Biotech, S.L., H2 2012 28
7TM Pharma A/S, H2 2012 29
GenKyoTex S.A., H2 2012 30
Angion Biomedica Corp., H2 2012 31
Virobay Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79

List of Figures
Number of Products under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

  • Zinc Bromide Industry Analysis, Trends and Forecast to 2020
    Global and Chinese Zinc Bromide (CAS7699-45-8) Industry, 2015 Market Research Report is a comprehensive research and 2015 market analysis by Prof Research, incorporating all the major phases and current market trends of in the Global and Chinese Zinc Bromide (CAS7699-45-8) Industry/market. The report commence with a brief introduction to the Zinc Bromide (CAS7699-45-8) along with [...]
  • Where is Healthcare Cloud Computing Market Going in Next 5 Years?
    Constant upsurge of IT n the field of healthcare has opened-up new business opportunities for cloud computing in the healthcare market. The basic requirement of cloud computing in healthcare industry is data-storage and data-integration that allows smooth data-access whenever required. Also, the need to collaborate a technologically advanced coordination between the patient and physician is [...]
  • Terminal Antennas Industry 2020 Forecasts for Global and Chinese Regions by Classification, Application & Manufacturing Technology
    Introduction: 2015 Terminal Antennas Industry Report – Global and Chinese Market 2015 Terminal Antennas Industry Report – Global and Chinese Market Scenario provide a detailed business insight on the trends of global and Chinese market. The report initially focuses on the existing technologies being used in the production of terminal antenas, the evolution of the [...]
  • Aluminum Heat Exchanger Consumption by Application and Type
    Global and Chinese Aluminum Heat Exchanger Industry, 2009-2019 Market Research Report is an in-depth market analysis of the current business situation and happenings of the Aluminum Heat Exchanger Industry. The report commence with a brief introduction to the industry, providing a description of the terminology used in the industry. The report further shares crucial stats [...]
  • Global and Chinese Calcium Heparin Market 2015 Analysis
    Synopsis – 2015 Calcium heparin Industry Report – Global and Chinese Market Scenario offers a thorough analysis of the entire Calcium Heparin industry. This report reviews each and every aspect of the Calcium Heparin industry and helps in effective decision making procedure.  A systematic breakup is provided to track down all possible barriers that can [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Orphan Diseases Therapeutics Market to 2018
    Published: 31-Dec-2011        Price: US 3500 Onwards        Pages: 0
    Report Summary Order Now With Pre-Publication Discount - GBI Research's new report will provide in depth analysis and expert insight into the "Orphan Diseases Therapeutics Market to 2018". The challenges in developing drugs for orphan indications are significant, but large pharmaceutical companies are showing increasing interest in the area and entering the market through strategic acquisitions and licensing agreements with smaller companies that have a strong research focus, as demonstrat......
  • Chronic Urticaria Or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    Published: 01-Jan-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Chronic Urticaria Or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging p......
  • Clostridium difficile (CDID) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Jan-2012        Price: US 3996 Onwards        Pages: 64
    GlobalData, the industry analysis specialist, has released its new report, “Clostridium difficile (CDID) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Clostridium difficile (CDID) Therapeutics market. The report identifies the key trends shaping and driving the global Clostridium difficile (CDID) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emer......
  • Polycythemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Jan-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Polycythemia Therapeutics market. The report identifies the key trends shaping and driving the global Polycythemia Vera Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging pla......
  • Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
    Published: 01-Jan-2012        Price: US 6995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Hepatitis C Therapeutics market. The report provides comprehensive information on Hepatitis C Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Hepatitis C Therapeutics market. It analyses t......
  • Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
    Published: 08-Jan-2012        Price: US 3500 Onwards        Pages: 159
    GBI Research, the leading business intelligence provider, has released its latest report, Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid......
  • Hepatic Encephalopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 01-Feb-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Hepatic Encephalopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatic Encephalopathy Therapeutics market. The report identifies the key trends shaping and driving the global Hepatic Encephalopathy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expec......
  • Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017
    Published: 21-Feb-2012        Price: US 3500 Onwards        Pages: 0
    Immunosuppressants holds a 64% Market Share of the Immunomodulators Market with More Products in the Pipeline than Immunostimulants This report provides insight about immunomodulators sales forecasts until 2017. Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classe......
  • Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 29-Feb-2012        Price: US 3995 Onwards        Pages: 57
    Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Portal Hypertension Therapeutics market. The report identifies the key trends shaping and driving the global Portal Hypertension Therapeutics ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs